KLB

KLB (Klotho Beta) is a single-pass transmembrane protein that acts as the essential co-receptor for the endocrine fibroblast growth factors, FGF19 and FGF21. While most fibroblast growth factors act locally (paracrine), FGF19 and FGF21 function as hormones that travel through the bloodstream to regulate systemic metabolism. However, these hormones have a low affinity for their primary receptors (FGFRs); they require KLB to act as a "molecular velcro," physically anchoring them to the cell surface so that they can trigger a signal.

KLB expression is highly restricted to specific metabolic tissues, primarily the liver, adipose tissue, and parts of the pancreas. This localization dictates where FGF19 and FGF21 can act. In the liver, KLB is required for FGF19 to inhibit bile acid synthesis after a meal, preventing the accumulation of toxic detergents. In both the liver and adipose tissue, KLB is the mandatory partner for FGF21, the hormone of the "starvation response" that promotes glucose uptake, fat burning, and systemic insulin sensitivity.

From a longevity perspective, the KLB-FGF21 axis is one of the most exciting areas of metabolic research. FGF21 is a "longevity-associated hormone": mice that overexpress it live up to 30-40% longer than normal. By orchestrating the beneficial effects of caloric restriction and exercise, the KLB complex serves as a primary hub for maintaining metabolic flexibility and protecting against the chronic diseases of aging, from fatty liver to type 2 diabetes.

The Molecular Velcro: Overcoming Low Affinity

The defining feature of endocrine FGFs (FGF19, 21, and 23) is their lack of a heparin-binding domain, which normally anchors other FGFs to the extracellular matrix. This absence allows them to enter the circulation and act as hormones, but it also means they cannot bind to their receptors (FGFRs) on their own.

KLB solves this problem by providing a high-affinity binding platform. It constitutively associates with FGFRs (particularly FGFR1c and FGFR4) and “waits” for the circulating hormone. When FGF21 or FGF19 arrives, it binds to the KLB extracellular domain, which then “presents” the hormone to the FGFR. This tripartite complex (Hormone-KLB-FGFR) is the only stable configuration that can initiate the downstream MAPK/ERK signaling cascade. Thus, KLB is the absolute gatekeeper of these metabolic signals.

Postprandial vs. Starvation: The Dual Role of KLB

KLB sits at the intersection of two opposite metabolic states. After feeding, bile acids in the intestine trigger the release of FGF19. This hormone: it travels to the liver, binds the KLB/FGFR4 complex, and sends a powerful signal to shut down bile acid production (by repressing the enzyme CYP7A1). This prevents “cholestasis” and ensures that the liver does not overproduce these potent detergents.

Conversely, during fasting, exercise, or protein restriction, the liver and fat produce FGF21. This hormone binds the KLB/FGFR1c complex in adipose tissue to stimulate glucose uptake and the “browning” of fat. It also signals back to the brain to modulate sugar preference and energy expenditure. KLB is the shared component that allows the body to interpret these diverse signals and maintain energy balance regardless of nutrient availability.

FGF21 Resistance and the Metabolic Trap

In conditions of chronic overnutrition, obesity, and type 2 diabetes, a state known as “FGF21 resistance” often develops. Despite having very high levels of circulating FGF21, the body stops responding to the signal. A major driver of this resistance is the downregulation of KLB in adipose tissue.

When KLB levels fall, the “velcro” is lost, and even massive amounts of FGF21 cannot activate the receptors. This breaks the fasting-response machinery, leading to impaired glucose handling and the inability to burn fat efficiently. Reversing this resistance—either by stabilizing KLB expression or by using engineered FGF21 mimetics that bind the remaining KLB more effectively—is a premier strategy for treating metabolic dysfunction-associated steatotic liver disease (MASLD).

KLB and the Biology of Longevity

The link between KLB signaling and lifespan is profound. In model organisms, overexpressing FGF21 (the primary KLB ligand): results in a remarkable extension of lifespan and healthspan. These long-lived mice remain lean, have extremely high insulin sensitivity, and are protected from the inflammatory hallmarks of aging.

This longevity effect is thought to be mediated through the KLB complex in the liver and hypothalamus, where it shifts the body into a “maintenance” mode similar to that seen in caloric restriction. By reducing growth-factor signaling (IGF-1) and improving the turnover of damaged organelles (mitophagy), the KLB-FGF21 axis acts as a systemic anti-aging program. As we age, maintaining the integrity of this axis is one of the most effective ways to preserve metabolic flexibility and prevent organ-wide decline.